European Union - English - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antithrombotic agents - possia, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-st-elevation myocardial infarction [nstemi] or st-elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - prasugrel hydrochloride - tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - prasugrel hydrochloride - tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - ticagrelor - tablet - 90mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - ticagrelor - tablet - 60mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actelion pharmaceuticals uk ltd - selexipag - tablet - 200microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actelion pharmaceuticals uk ltd - selexipag - tablet - 400microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actelion pharmaceuticals uk ltd - selexipag - tablet - 600microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actelion pharmaceuticals uk ltd - selexipag - tablet - 800microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actelion pharmaceuticals uk ltd - selexipag - tablet - 1mg